Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
VFEND Voriconazole Aspergillosis, Invasive List with clinical criteria and/or conditions Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Withdrawn
Norprolac Quinagolide hydrochloride Hyperprolactinemia Do not list Complete
Ebixa Memantine hydrochloride Dementia (Alzheimer type), moderate to severe Do not list Complete
Yasmin Drospirenone /ethinyl estradiol Contraceptive, oral List Complete
Telzir Fosamprenavir calcium HIV infection List in a similar manner to other drugs in class Complete
Strattera Atomoxetine hydrochloride Attention deficit hyperactivity disorder Do not list Complete
Aldurazyme Laronidase Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie Do not list Complete